Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Samir H. Barghout"'
Autor:
Samir H. Barghout, Ahmed Aman, Kazem Nouri, Zachary Blatman, Karen Arevalo, Geethu E. Thomas, Neil MacLean, Rose Hurren, Troy Ketela, Mehakpreet Saini, Moustafa Abohawya, Taira Kiyota, Rima Al-Awar, Aaron D. Schimmer
Publikováno v:
JCI Insight, Vol 6, Iss 5 (2021)
TAK-243 is a first-in-class inhibitor of ubiquitin-like modifier activating enzyme 1 that catalyzes ubiquitin activation, the first step in the ubiquitylation cascade. Based on its preclinical efficacy and tolerability, TAK-243 has been advanced to p
Externí odkaz:
https://doaj.org/article/d082e4930596459b8898e21f8ca1f16d
Autor:
Samir H. Barghout
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 21:214-230
Drug discovery in the scope of cancer therapy has been focused on conventional agents that nonselectively induce DNA damage or selectively inhibit the activity of key oncogenic molecules without affecting their protein levels. An emerging therapeutic
Autor:
Zachary Blatman, Rose Hurren, Neil MacLean, Ahmed Aman, Taira Kiyota, Kazem Nouri, Rima Al-awar, Moustafa Abohawya, Mehakpreet Saini, Karen Arevalo, Samir H. Barghout, Aaron D. Schimmer, Troy Ketela, Geethu E. Thomas
Publikováno v:
JCI Insight, Vol 6, Iss 5 (2021)
JCI Insight
JCI Insight
TAK-243 is a first-in-class inhibitor of ubiquitin-like modifier activating enzyme 1 that catalyzes ubiquitin activation, the first step in the ubiquitylation cascade. Based on its preclinical efficacy and tolerability, TAK-243 has been advanced to p
Autor:
Aaron D. Schimmer, Samir H. Barghout
Publikováno v:
Pharmacological reviews. 73(1)
Post-translational modifications of cellular substrates with ubiquitin and ubiquitin-like proteins (UBLs), including ubiquitin, SUMOs, and neural precursor cell-expressed developmentally downregulated protein 8, play a central role in regulating many
Autor:
Neil MacLean, Shawn Brennan, Adam C. Smith, Rose Hurren, Allison Berger, Xiaoming Wang, Razq Hakem, Marcela Gronda, Mark D. Minden, Sara Farshchi Zarabi, Simon Kavanagh, Tary Traore, G. Wei Xu, Aaron D. Schimmer, Emil F. Pai, Samir H. Barghout, Ondrej Halgas, Michael Milhollen, Marc L. Hyer, Parasvi S. Patel, Danny V. Jeyaraju
Publikováno v:
Leukemia. 33:37-51
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme
Autor:
Neil MacLean, Takenobu Nii, Michael Andreeff, Marcela Gronda, Lauren Heese, Andrew B. Leber, Emil F. Pai, Grace Egan, Hagop M. Kantarjian, Samir H. Barghout, Jo Ishizawa, Jonathan St-Germain, R. Eric Davis, Todd M. Link, Mark F. Mabanglo, Sarah F. Zarabi, Walid A. Houry, Rose Hurren, Martin Stogniew, Wencai Ma, Ondrej Halgas, Brian Raught, Yulia Jitkova, Kensuke Kojima, Keith S. Wong, Man Chun John Ma, Mark D. Minden, Vivian Ruvolo, Gautam Borthakur, Ran Zhao, Aaron D. Schimmer, Yuki Nishida
Publikováno v:
Cancer Cell
Summary The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein quality control by degrading misfolded proteins. Using genetic and chemical approaches, we showed that hyperactivation of the protease selectively
Autor:
Anna Rydlewski, Jaime O. Claudio, Karen Yee, Andre C. Schuh, Aaron D. Schimmer, Mahadeo A. Sukhai, Sanduni U. Liyanage, Thirushi P. Siriwardena, Mark D. Minden, Rose Hurren, Dawn Maze, Samir H. Barghout, Steven M. Chan, Amr Rostom, Hassan Sibai, Emily Heath, Dina Khalaf, Vikas Gupta, Marcela Gronda, Tracy Stockley, Tong Zhang, Andrzej Lutynski, Simon Kavanagh, Suzanne Kamel-Reid
Publikováno v:
Leukemia research. 68
We evaluated outcomes of 100 patients with high risk AML treated with Ida-FLAG induction as first-line therapy. 72 achieved remission with one cycle; 19 did not. High risk cytogenetics and TP53 mutations were associated with failure to achieve remiss
Autor:
Zachary Blatman, Rose Hurren, Aaron D. Schimmer, Geethu E. Thomas, Samir H. Barghout, Neil MacLean, G. Wei Xu
Publikováno v:
Blood. 132:1350-1350
UBA1 is the major ubiquitin-activating enzyme that initiates the ubiquitylation cascade whereby proteins are tagged with mono- or polyubiquitin to mark them for proteasomal degradation or modify their functions. Despite having equal levels of UBA1 pr
Publikováno v:
Biochemical and biophysical research communications. 468(1-2)
Ovarian cancer is the fifth leading cause of cancer-related mortalities in women. Epithelial ovarian cancer (EOC) represents approximately 90% of all ovarian malignancies. Most EOC patients are diagnosed at advanced stages and current chemotherapy re
Autor:
Marcela Gronda, Mark D. Minden, Danny V. Jeyaraju, John E. Dick, Eric R. Lechman, Aaron D. Schimmer, Samir H. Barghout, Dilshad H. Khan, Changjiang Xu, Yulia Jitkova, Xiaoming Wang, Sanduni U. Liyanage, Joelle Soriano, David Sharon, Gary D. Bader, Veronique Voisin, Rose Hurren, Steven M. Chan, Neil MacLean
Publikováno v:
Blood. 130:881-881
The vast majority of mitochondrial proteins are encoded in the nucleus, translated in the cytoplasm and then imported into the mitochondria. A subset of these imported proteins are folded into their mature and functional forms in the mitochondrial in